Intended for U.S. scientific audiences only.
BMS at #EULAR 2019
Investigating personalized approaches and addressing unmet immune-mediated disease patient needs.
t the European Congress of Rheumatology 2019 (EULAR 2019 – June 12-15 in Madrid), we’re presenting 27 Bristol-Myers Squibb-sponsored abstracts, underscoring our commitment to informing better, more personalized approaches in immune-mediated diseases where treatment options are limited or improvements are needed. The presented data include clinical and real-world results that support our focuses on furthering precision medicine in rheumatoid arthritis and addressing patient unmet needs in juvenile idiopathic arthritis. Findings on new modes of action being explored as part of our early Immunoscience program will also be shared.